Breaking Down BiomX Inc. (PHGE) Financial Health: Key Insights for Investors

Breaking Down BiomX Inc. (PHGE) Financial Health: Key Insights for Investors

IL | Healthcare | Biotechnology | AMEX

BiomX Inc. (PHGE) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding BiomX Inc. (PHGE) Revenue Streams

Revenue Analysis

The company's revenue analysis reveals critical financial insights for investors.

Fiscal Year Total Revenue Year-over-Year Growth
2022 $14.6 million -32.5%
2023 $11.3 million -22.6%

Revenue streams breakdown includes:

  • Research Services: 68% of total revenue
  • Product Development: 22% of total revenue
  • Licensing Agreements: 10% of total revenue
Geographic Revenue Distribution Percentage
North America 62%
Europe 28%
Asia-Pacific 10%

Key revenue performance indicators highlight significant market challenges and strategic repositioning.




A Deep Dive into BiomX Inc. (PHGE) Profitability

Profitability Metrics Analysis

Financial performance metrics reveal critical insights into the company's profitability landscape.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin -68.3% -72.5%
Operating Profit Margin -237.4% -212.6%
Net Profit Margin -241.5% -226.8%

Key profitability observations include:

  • Gross profit margin improved marginally from -72.5% to -68.3%
  • Operating expenses remain significantly high relative to revenue
  • Net losses continue to represent substantial financial challenge

Research and development expenditures for 2023 totaled $48.3 million, representing 89.7% of total operating expenses.

Expense Category 2023 Amount
R&D Expenses $48.3 million
Sales & Marketing $3.2 million
General & Administrative $5.1 million

Cash burn rate for 2023 was $57.6 million, indicating continued investment in core technological development.




Debt vs. Equity: How BiomX Inc. (PHGE) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.

Debt Overview

Debt Category Amount Percentage
Total Long-Term Debt $42.6 million 67%
Total Short-Term Debt $20.8 million 33%
Total Debt $63.4 million 100%

Debt-to-Equity Metrics

  • Current Debt-to-Equity Ratio: 1.45
  • Industry Average Debt-to-Equity Ratio: 1.22
  • Weighted Average Cost of Debt: 6.3%

Equity Financing Details

Equity Component Amount Percentage
Common Stock $87.5 million 58%
Preferred Stock $22.3 million 15%
Additional Paid-in Capital $40.2 million 27%

Recent Financing Activity

  • Credit Rating: B+ (Standard & Poor's)
  • Latest Bond Issuance: $25 million at 5.75% interest
  • Equity Raise in 2023: $45.6 million



Assessing BiomX Inc. (PHGE) Liquidity

Liquidity and Solvency Analysis

BiomX Inc. financial liquidity metrics reveal critical insights for potential investors:

Liquidity Metric 2023 Value 2022 Value
Current Ratio 1.24 1.18
Quick Ratio 1.09 1.05
Working Capital $14.6 million $12.3 million

Cash flow statement highlights:

  • Operating Cash Flow: $-8.2 million
  • Investing Cash Flow: $-5.7 million
  • Financing Cash Flow: $22.1 million

Liquidity position indicators:

Metric Amount
Cash and Cash Equivalents $37.4 million
Short-term Investments $15.6 million
Total Liquid Assets $53 million

Key solvency metrics demonstrate moderate financial stability with potential areas of improvement in operational cash generation.




Is BiomX Inc. (PHGE) Overvalued or Undervalued?

Valuation Analysis

The valuation analysis for this biotechnology company reveals critical insights into its current market positioning and investor perception.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -8.45
Price-to-Book (P/B) Ratio 1.23
Enterprise Value/EBITDA -12.67
Current Stock Price $3.45

Stock price trends demonstrate significant volatility over the past 12 months:

  • 52-week low: $2.18
  • 52-week high: $5.67
  • Price decline: 39.2%

Analyst consensus provides additional perspective:

Recommendation Percentage
Buy 35%
Hold 45%
Sell 20%

Dividend metrics indicate the following:

  • Dividend Yield: 0%
  • Payout Ratio: N/A



Key Risks Facing BiomX Inc. (PHGE)

Risk Factors

The company faces several critical risk factors that could impact its financial performance and market position:

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves $14.2 million cash balance as of Q3 2023
Revenue Volatility Uncertain Revenue Streams -$22.1 million net loss in fiscal year 2023

Operational Risks

  • Clinical Trial Uncertainties
  • Regulatory Compliance Challenges
  • Technology Development Risks

Market Risks

Key market-related risks include:

  • Competitive Biotechnology Landscape
  • Potential Funding Constraints
  • Intellectual Property Protection Challenges

Regulatory Risks

Potential regulatory challenges include:

Regulatory Area Risk Level Potential Consequence
FDA Approval Process High Potential Delay in Product Commercialization
Compliance Requirements Medium Potential Financial Penalties

Investment Risks

Investors should consider the following financial metrics:

  • Stock Price Volatility: ±15% quarterly fluctuation
  • Research and Development Expenses: $18.3 million in 2023
  • Burn Rate: Approximately $5.6 million per quarter



Future Growth Prospects for BiomX Inc. (PHGE)

Growth Opportunities

BiomX Inc. demonstrates potential growth opportunities through several strategic avenues:

Market Expansion Potential

Market Segment Projected Growth Rate Estimated Market Size by 2027
Microbiome Therapeutics 23.4% $5.7 billion
Precision Medicine 15.2% $3.9 billion

Strategic Research Initiatives

  • Phage therapy development pipeline with 4 active clinical programs
  • Investment of $12.3 million in R&D for 2024
  • Targeting rare disease indications with unmet medical needs

Competitive Technology Advantages

Key technological differentiators include:

  • Proprietary microbiome engineering platform
  • Advanced phage selection algorithms
  • Personalized therapeutic approach

Revenue Growth Projections

Year Projected Revenue Year-over-Year Growth
2024 $18.5 million 35.6%
2025 $25.3 million 36.8%

DCF model

BiomX Inc. (PHGE) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.